Apolipoprotein C3 Is Downregulated in Patients With Inflammatory Bowel Disease.
Journal
Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142
Informations de publication
Date de publication:
01 06 2022
01 06 2022
Historique:
received:
01
11
2021
accepted:
20
04
2022
pubmed:
19
5
2022
medline:
30
6
2022
entrez:
18
5
2022
Statut:
epublish
Résumé
Inflammatory bowel disease (IBD) has been associated with an abnormal lipid profile. Apolipoprotein C-III (ApoC3) is a key molecule of triglyceride metabolism that is known to be related to inflammation and cardiovascular disease. In this study, we aim to study whether ApoC3 serum levels differ between patients with IBD and controls and whether the hypothetical disturbance of ApoC3 can be explained by IBD characteristics. This is a cross-sectional study that included 405 individuals, 197 patients with IBD and 208 age-matched and sex-matched controls. ApoC3 and standard lipid profiles were assessed in patients and controls. A multivariable analysis was performed to analyze whether ApoC3 serum levels were altered in IBD and to study their relationship to IBD characteristics. After fully multivariable analysis including cardiovascular risk factors, use of statins, and changes in lipid profile caused by the disease itself, patients with IBD showed significant lower serum levels of ApoC3 (beta coef. -1.6 [95% confidence interval -2.5 to -0.7] mg/dL, P = 0.001). Despite this, inflammatory markers, disease phenotypes, or disease activity of IBD was not found to be responsible for this downregulation. Apolipoprotein C3 is downregulated in patients with IBD.
Identifiants
pubmed: 35584319
doi: 10.14309/ctg.0000000000000500
pii: 01720094-202206000-00002
pmc: PMC9236603
doi:
Substances chimiques
APOC3 protein, human
0
Apolipoprotein C-III
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00500Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Références
Sappati Biyyani RSR, Putka BS, Mullen KD. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J Clin Lipidol 2010;4(6):478–82.
Koutroumpakis E, Ramos-Rivers C, Regueiro M, et al. Association between long-term lipid profiles and disease severity in a large cohort of patients with inflammatory bowel disease. Dig Dis Sci 2016;61(3):865–71.
Agouridis AP, Elisaf M, Milionis HJ. An overview of lipid abnormalities in patients with inflammatory bowel disease. Ann Gastroenterol 2011;24(3):181–7.
Bobik A. Editorial: Apolipoprotein CIII and atherosclerosis;beyond effects on lipid metabolism. Circulation 2008;118(7):702–4.
Hussain A, Ballantyne CM, Saeed A, et al. Triglycerides and ASCVD risk reduction: Recent insights and future directions. Curr Atheroscler Rep 2020;22(7):1–10. doi: 10.1007/s11883-020-00846-8
doi: 10.1007/s11883-020-00846-8
Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-Function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014;371(1):32–41.
Crosby J, Peloso GM, Auer PL, et al. Loss-of-Function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014;371(1):22–31.
Zewinger S, Reiser J, Jankowski V, et al. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat Immunol 2020;21(1):30–41.
Wu NQ, Li S, Zhang Y, et al. Plasma apoCIII levels in relation to inflammatory traits and metabolic syndrome in patients not treated with lipid-lowering drugs undergoing coronary angiography. Biomed Environ Sci 2017;30(1):1–9.
Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet 1980;315(8167):514.
Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: Management of Crohn's disease in adults. Am J Gastroenterol 2018;113(4):481–517.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987;317(26):1625–9.
Quevedo-Abeledo JC, Sánchez-Pérez H, Tejera-Segura B, et al. Differences in capacity of high-density lipoprotein cholesterol efflux between patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Care Res 2020;73(11):1590–1596.
Tejera-Segura B, Macía-Díaz M, Machado JD, et al. HDL cholesterol efflux capacity in rheumatoid arthritis patients: Contributing factors and relationship with subclinical atherosclerosis. Arthritis Res Ther 2017;19(1):1–10. doi: 10.1186/s13075-017-1311-3
doi: 10.1186/s13075-017-1311-3
Sánchez-Pérez H, Quevedo-Abeledo JC, De Armas-Rillo L, et al. Impaired HDL cholesterol efflux capacity in systemic lupus erythematosus patients is related to subclinical carotid atherosclerosis. Rheumatol (United Kingdom) 2020;59(10):2847–56.
De Armas-Rillo L, Quevedo-Abeledo JC, De Vera-González A, et al. Proprotein convertase subtilisin/kexin type 9 in the dyslipidaemia of patients with axial spondyloarthritis is related to disease activity. Rheumatol (United Kingdom). 2021;60(5):2296–306.
Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: The impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011;70(3):482–7.
Hernández-Camba A, Carrillo-Palau M, Ramos L, et al. Carotid plaque assessment reclassifies patients with inflammatory bowel disease into very-high cardiovascular risk. J Clin Med 2021;10(8):1–10. doi: 10.3390/jcm10081671
doi: 10.3390/jcm10081671
Feng W, Chen G, Cai D, et al. Inflammatory bowel disease and risk of ischemic heart disease: An updated meta-analysis of cohort studies. J Am Heart Assoc 2017;6(8):1–9. doi: 10.1161/JAHA.117.005892
doi: 10.1161/JAHA.117.005892